Lamotrigine (All indications) updated on 04-22-2025

Elective/induced termination of pregnancy

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S19332
R81952		 Moore (Lamotrigine) (Indication NOS), 2025 Elective termination of pregnancy during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Matched 1.17 [1.01;1.36] 351/1,846   2,734/17,128 3,085 1,846
ref
S12677
R47910		 Hosny, 2021 Induced abortion 1st trimester prospective cohort unexposed, sick Adjustment: No 8.20 [0.13;511.93] C 0/3   0/21 0 3
ref
S8913
R30124		 Miškov (Lamotrigine) (Controls unexposed, disease free), 2016 Artificial abortion during pregnancy (anytime or not specified) prospective cohort unexposed, disease free excluded Adjustment: No 10.77 [0.43;270.26] C
excluded (control group) 		1/37   0/128 1 37
ref
S8914
R30130		 Miškov (Lamotrigine) (Controls unexposed, sick), 2016 Artificial abortion during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No 0.30 [0.01;8.72] C 1/37   0/4 1 37
ref
S8972
R30408		 Holmes (Lamotrigine) (Mixed indications), 2011 Elective termination 1st trimester prospective cohort unexposed, disease free Adjustment: No 1.81 [0.10;33.72] C 4/948   0/190 4 948
ref
Total 4 studies 1.17 [1.01;1.36] 3,090 2,834
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Moore (Lamotrigine) (Indication NOS), 2025Moore, 2025 1 1.17[1.01; 1.36]3,0851,84699%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: low Hosny, 2021Hosny, 2021 8.20[0.13; 511.93]030%ROB confusion: criticalROB selection: moderateROB classification: unclearROB missing: lowROB mesure: unclearROB reporting: moderate Miškov (Lamotrigine) (Controls unexposed, sick), 2016Miškov, 2016 2 0.30[0.01; 8.72]1370%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: criticalROB mesure: moderateROB reporting: moderate Holmes (Lamotrigine) (Mixed indications), 2011Holmes, 2011 3 1.81[0.10; 33.72]49480%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Total (4 studies) I2 = 0% 1.17[1.01; 1.36]3,0902,8340.220.01.0ROB: A: confounding, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Indication NOS; 2: Lamotrigine) (Controls unexposed, sick; 3: Lamotrigine) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.17[1.01; 1.36]3,0902,8340%NAMoore (Lamotrigine) (Indication NOS), 2025 Hosny, 2021 Miškov (Lamotrigine) (Controls unexposed, sick), 2016 Holmes (Lamotrigine) (Mixed indications), 2011 4 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.17[1.01; 1.36]3,0892,7940%NAMoore (Lamotrigine) (Indication NOS), 2025 Holmes (Lamotrigine) (Mixed indications), 2011 2 unexposed, sickunexposed, sick 1.25[0.05; 31.47]14033%NAHosny, 2021 Miškov (Lamotrigine) (Controls unexposed, sick), 2016 2 Tags Adjustment   - No  - No 1.39[0.20; 9.76]59880%NAHosny, 2021 Miškov (Lamotrigine) (Controls unexposed, sick), 2016 Holmes (Lamotrigine) (Mixed indications), 2011 3   - Yes  - Yes 1.17[1.01; 1.36]3,0851,846 -NAMoore (Lamotrigine) (Indication NOS), 2025 1 MatchedMatched 1.17[1.01; 1.36]3,0851,846 -NAMoore (Lamotrigine) (Indication NOS), 2025 1 All studiesAll studies 1.17[1.01; 1.36]3,0902,8340%NAMoore (Lamotrigine) (Indication NOS), 2025 Hosny, 2021 Miškov (Lamotrigine) (Controls unexposed, sick), 2016 Holmes (Lamotrigine) (Mixed indications), 2011 40.120.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-5.05.12.5310.000Moore (Lamotrigine) (Indication NOS), 2025Hosny, 2021Miškov (Lamotrigine) (Controls unexposed, sick), 2016Holmes (Lamotrigine) (Mixed indications), 2011

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 8913

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.18[1.01; 1.37]3,0902,8310%NAMoore (Lamotrigine) (Indication NOS), 2025 Miškov (Lamotrigine) (Controls unexposed, disease free), 2016 Holmes (Lamotrigine) (Mixed indications), 2011 3 unexposed, sick controlsunexposed, sick controls 1.25[0.05; 31.47]14033%NAHosny, 2021 Miškov (Lamotrigine) (Controls unexposed, sick), 2016 20.510.01.0